All companies › UPB

UPB · Upstream Bio, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells5
Research cases0
Last filing2026-09-16

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-16 — Ambrose Allison · sold 485 @ $5.49 2026-09-16 — GRAY MICHAEL · sold 853 @ $5.49 2026-09-16 — Houghton Adam · sold 700 @ $5.49 2026-09-16 — Sutherland Everett Rand · sold 2,095 @ $5.49 2026-09-16 — Deykin Aaron · sold 895 @ $5.49
2026-09-162026-09-16

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Ambrose Allison General Counsel
GRAY MICHAEL CFO and COO
Houghton Adam Chief Business Officer
Sutherland Everett Rand Chief Executive Officer, Director
Deykin Aaron Chief Medical Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $UPB is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-16', 'insider_name': 'Ambrose Allison', 'insider_title': 'General Counsel', 'transaction_type': 'Open-market sell', 'shares': 485.0, 'price': 5.49, 'value': 2662.65, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'GRAY MICHAEL', 'insider_title': 'CFO and COO', 'transaction_type': 'Open-market sell', 'shares': 853.0, 'price': 5.49, 'value': 4682.97, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Houghton Adam', 'insider_title': 'Chief Business Officer', 'transaction_type': 'Open-market sell', 'shares': 700.0, 'price': 5.49, 'value': 3843.0, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Sutherland Everett Rand', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 2095.0, 'price': 5.49, 'value': 11501.55, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Deykin Aaron', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 895.0, 'price': 5.49, 'value': 4913.55, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for UPB today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.